Contraindications to the introduction of a vaccine against coronavirus infection are indicated in the instructions for their use. The main contraindications (on the example of Sputnik V, the Russian name "Gam-COVID-Vac") are hypersensitivity to any component of the vaccine, a history of severe allergic reactions, exacerbation of chronic diseases, pregnancy and breastfeeding, age up to 18 years and severe post-vaccination complications if they were after previous vaccinations. The full list and exact wording of contraindications can be read in the instructions for the use of the vaccine.

Register of vaccinated against COVID-19 in Russia

In mid-December 2020, a register of COVID-19 vaccinated against coronavirus appeared in Russia. The launch of the system coincided with a massive vaccination campaign across the country. Read more here.

2022

Rostec and ISKCH agree on further trials of a single vaccine against coronavirus and influenza

The Human Stem Cell Institute (ISKJ) and Rostec pharmaceutical holding Natsimbio have signed an agreement on clinical research, production and commercialization of a jointly developed combined vaccine for the prevention of influenza and coronavirus infection. The company "Natsimbio" announced this on December 29, 2022. Read more here.

The effectiveness of the Sputnik V vaccine against hospitalization from the Omicron strain is 97%

June 15, 2022 NICEM named after N.F. Gamalei announced the publication of the results of a study of the effectiveness of the Sputnik V vaccine against hospitalization from the Omikron strain (B.1.1.529), conducted by a team of scientists from the City Clinical Hospital No. 67 named after L.A. Vorokhobov and the Gamaleya Center. According to the results of the study, the effectiveness of the two-component Sputnik V vaccine against all types of hospitalizations from the Omicron strain is 97% with booster 3 and 4 doses (single-component Sputnik Light or repeated vaccination with Sputnik V). Read more here.

2021

Vector: The effectiveness of Russian vaccines against delta coronavirus exceeds 90%

In early August 2021, the Yekaterinburg Research Institute of Viral Infections "Vector" of Rospotrebnadzor announced that the effectiveness of Russian vaccines against coronavirus COVID-19 in the case of delta and delta-plus strains exceeds 90%.

The effectiveness of vaccines decreases slightly and, according to the latest data, still remains at a level above 90%, - said the head of the research institute Alexander Semenov.

According to him, foreign drugs also demonstrate high effectiveness. Post-vaccination antibodies have a neutralizing effect and are very effective against delta and delta plus infections. However, with the delta and delta plus strains, "slightly more antibodies are required compared to the classic version of the virus," he added.

Vector: The effectiveness of Russian vaccines against delta COVID-19 exceeds 90%

For all the latest tests, which were carried out comprehensively and are carried out constantly, including Rospotrebnadzor specialists, for virus neutralization, we see that the antibodies that are produced as a result of domestic vaccines work effectively, Semenov said.

He stressed that by the beginning of August 2021 it makes no sense to change the composition of vaccines, since "all circles of registration and clinical trials will have to go through again."

In June 2021, the head of Rospotrebnadzor Anna Popova said that the delta plus strain was found in one patient who suffered a mild illness. The third wave of the coronavirus epidemic in Russia is associated with the spread of the Indian delta strain.

The WHO at the end of July 2021 stated that the "delta" -stamm will dominate the world in the coming months, if an even more contagious option does not appear. According to the organization, this mutation of the virus was detected in 19 out of 38 EU countries, the share of delta cases in them was 68.3^[1]

Natsimbio buys coronavirus vaccines worth 58.5 billion rubles

In July 2021, Natsimbio purchased vaccines against the coronavirus COVID-19 for a total of 58.5 billion rubles. This is evidenced by the data of the unified information system in the field of procurement. Read more here.

60 billion rubles from the budget were spent on the production of vaccines against COVID-19 in Russia

60 billion rubles from the budget were spent on the production of vaccines against coronavirus COVID-19 in Russia. This was announced in mid-May 2021 by the Ministry of Industry and Trade.

The department noted that the maximum purchase cost of one dose of each vaccine is approximately the same. The cheapest EpiVacCorona is 842 rubles, in second place is KoviVac - 866 rubles, the most expensive on the list is the Sputnik V vaccine (866.81 rubles per dose).

In mid-May 2021, the FAS agreed on the maximum selling price for the Sputnik Light vaccine. It will amount to 342.36 rubles excluding VAT per dose. After registering the price, the vaccine will go into civilian circulation.

60 billion rubles from the budget were spent on the production of vaccines against COVID-19 in the Russian Federation

The purchase of the vaccine is carried out in accordance with the price registered in the Federal Antimonopoly Service, based on the production capabilities of the sites where they are produced. In Russia, by mid-May 2021, four vaccines against coronavirus were registered. Sputnik V has 7 manufacturers, Sputnik Light has 8, EpiVacCorona has 3, and KoviVac is produced only at the site of its creator, the Chumakov Center.

It is planned to increase the production of vaccines against coronavirus, including through the attraction of funds from private investors. The government expects that 68.6 million Russians, or 60% of the country's population, will be able to get vaccinated against coronavirus without taking into account those who have had it, which is necessary to create collective immunity to this disease. about the words of Prime Minister Mikhail Mishustin, more than 24 million Russians have already been vaccinated with at least the first dose of the drug. He spoke about this, speaking with a report on the work of the government in the State Duma on May 12, 2021.

Earlier, Deputy Prime Minister Tatyana Golikova said that in the first half of 2021, it is planned to release 88 million doses of coronavirus vaccine. According to her, in order to achieve population immunity, it is necessary to vaccinate 68.6 million Russians without taking into account those who have been ill and minors.^[2]

The AstraZeneca vaccine produced in Russia was called "R-Covi"

On March 12, 2021, the name became known, coronavirus vaccines COVID-19 which, under the license of the British pharmaceutical company AstraZeneca Oxford University , will be produced by the Russian company "." R-Pharm More. here

Chumakov Center: Russian polio vaccine protects against COVID-19

In early May 2021, the Federal Scientific Center for Research and Development of Immunobiological Preparations named after M.P. Chumakov RAS announced that he had proven the effectiveness of the polio vaccine as a means of combating the coronavirus COVID-19. Read more here.

2020

The structure of "Sberbank" can become a single supplier of vaccines against COVID-19 on public procurement

On December 1, 2020, it became known that the structure of Sberbank Immunotechnologies could become a single supplier of vaccines for the prevention of COVID-19. Read more here.

COVID-19 vaccine developed that can be inhaled

Russia has developed a vaccine against the coronavirus COVID-19, which can be inhaled. This became known on October 15, 2020. Read more here.

Russia refused to purchase foreign vaccines against COVID-19

On September 10, 2020, it became known that Russia refused to purchase foreign vaccines against the coronavirus COVID-19. As explained to Izvestia in the Permanent Mission of the Russian Federation to the UN Office in Geneva, other states that have powerful potential in the field of biotechnology adhere to similar positions.

Taking into account the fact that vaccination of the Russian population against COVID-19 is supposed to be carried out with domestically produced drugs, our country has no need to accept obligations for the purchase of vaccines under COVAX, the permanent mission noted.

Russia refused to purchase foreign vaccines against coronavirus

At the same time, Russia plans to join the WHO COVAX mechanism, the task of which is to fairly distribute vaccines against the new coronavirus infection to all countries of the world. It is expected that Moscow will soon offer its development in the international portfolio of drugs for COVID-19. In total, up to 15 vaccines developed in different states should be included there, according to the newspaper's publication of September 10, 2020.

A number of states, including the United Kingdom, the United States and Japan, are in no hurry to join COVAXy and are limited to bilateral deals for the supply of vaccines. At the same time, the WHO explained that the response to the pandemic should be collective.

Three organizations will coordinate COVAX: WHO, the global vaccine and immunization alliance Gavi, and the CEPI Epidemic Preparedness Innovation Coalition. According to diplomats, the parameters of specific procurement obligations (the number of vaccines, prices, etc.) will be agreed with manufacturers directly.

According to WHO, by September 10, 2020, more than 200 vaccines against COVID-19 are being developed in the world, 30 of them are already being tested in humans. The WHO believes that the results of drug trials will appear in the first half of 2021.^[3]

Ministry of Health of the Russian Federation: vaccines against coronavirus will be subject to digital labeling

Vaccines against coronavirus COVID-19 Russia in will be subject to digital labeling. This was announced on Center for the Development of Promising Technologies June 25, 2020 by the deputy head of the digital development department information technology Ministry of Health and Evgenia Merkulova.

Mandatory labeling is introduced in our country from July 1, and as soon as vaccines against coronavirus appear, they are subject to mandatory labeling and will be marked. All information about them will be entered into the monitoring system, which will allow us to track the volume and number of those vaccines, as well as where they are delivered, for which medical institutions are distributed and, accordingly, also monitor price changes, she said.

Vaccines against coronavirus COVID-19 in Russia are subject to digital labeling

According to Merkulova, thanks to digital labeling, it is possible to track drugs that are recommended for the treatment of the new coronavirus, since they are already included in the monitoring system.

The head of the Gamaleya National Research Center (NRC) of Epidemiology and Microbiology, Alexander Gintsburg, said that a person vaccinated against coronavirus will be protected from infection for two years. The first industrial batch of coronavirus vaccine in the Russian Federation is planned to be received in early autumn 2020, the head said. Rospotrebnadzor Anna Popova

In May 2020, the Russian government published a decree according to which labeling will become a mandatory licensing requirement for drug manufacturers from July 1. According to the document, all medicines of manufacturers must be registered without fail in the monitoring system for the movement of drugs for human use.^[4]

Ministry of Health: The genome of the coronavirus has been completely deciphered in Russia

March 19, 2020 Ministry of Health of the Russian Federation reported that Russian scientists managed to completely decipher genome coronavirus a new type. This will help in the development of a vaccine and a drug for the treatment of the disease.

Specialists of the Federal State Budgetary Institution "Research Institute of Influenza named after A. A. Smorodintsev" of the Ministry of Health of Russia were sequenced from material from a patient with COVID-19 the first complete genome of the SARS-CoV-2 coronavirus from Russia, the Russian News Agency quoted TASS as saying the press service of the department.

Scientists of the National Research Institute (Research Institute) of Influenza named after A. A. Smorodintsev of the Ministry of Health of the Russian Federation were able to sequence the first complete genome of the new coronavirus

As noted by the acting director of the Research Institute of Influenza named after A. A. Smorodintsev, Doctor of Medical Sciences Dmitry Lioznov, genetic analysis is important for understanding the evolution of the new coronavirus. Since this virus is new, it is critical to be able to determine the path of its spread and entry into the territory in Russia, as well as its changes, he stressed.

It was possible to decipher the genome from material taken from one of the Russian patients. The information received by Russian scientists was sent to the WHO database in order to be accessed by other research groups.

Russia already had at its disposal the gene of the coronavirus, which was handed over to China in January 2020. Then, without a live strain of the new virus, scientists have already begun to develop a vaccine against it.

Russian scientists photographed the coronavirus and deciphered its genome

The laboratory of the Novosibirsk State Scientific Center for Virology and Biotechnology "Vector" took pictures of the new coronavirus under a microscope. By March 19, 2020, Vektore is developing a vaccine against the disease. Representatives of the Novosibirsk Virological Center reported that they already have prototypes of a vaccine against COVID-19 and have begun testing on laboratory animals.

Researchers from other countries are also analyzing local variations in the coronavirus. Scientists at the University of Valencia in Spain claim that the genome of the virus is constantly changing and 16 variations have already been found in Brazil.^[5]

Biocad develops a vaccine against coronavirus

On March 18, 2020, Biocad announced to Zdrav.Expert the start of development of an mRNA vaccine against coronavirus SARS-COV-2 The development will be carried out on the basis of previous developments in the creation of mRNA-oncovaccine, in this area the company has accumulated extensive experience. The first animal studies will be held at the end of April 2020. Read more here.

Notes

Источник — «https://tadviser.com/index.php/Article:Vaccines_against_coronavirus_COVID-19_in_Russia»

The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article
If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible.

Simple Link

How to create a "smart plant": Key characteristics of a modern digital enterprise 7300

Model Studio CS: How to use BIM to give new impetus to the development of the fuel and energy complex 4500

Vaccines against coronavirus COVID-19 in Russia

Content